Instylla

Join us on Saturday, October 18, at the Shelborne in Miami Beach at 7:30 pm ET for dinner and a presentation event with Dr. David Tahour and Dr. Edgar St. Amour. Learn about the future of liquid embolics, the Embrace Hydrogel Embolic System. Reserve your seat here. https://shorturl.at/4hruP

Embrace the Case. - 69-year-old male - Advanced HCC, Segment V liver, 4.7 cm with residual 1.5 cm enhancement - Prior systemic and locoregional therapy, extrahepatic disease present Treated with Embrace® HES. - Complete Response per mRECIST at 30 days - Complete Response maintained at 90 days - No local tumor progression - No revascularization Conclusion: Sustained local disease control in an advanced-stage HCC patient with limited therapeutic options. This case underscores the effectiveness of embolization in an advanced-stage HCC patient with limited therapeutic options, demonstrating sustained local disease control despite prior systemic therapy, bland embolization, and extrahepatic disease View the full case: https://lnkd.in/giS6Anjz #EmbraceHES #Instylla #InterventionalRadiology #Embolization #IR #InterventionalOncology #HCC

Embrace® HES is giving IRs a new option for treating hypervascular tumors. But a new option alone doesn't drive adoption. Physician experience and patient outcomes do. That's why we're so excited to sponsor this BackTable Vascular and Interventional episode, where host Venkatesh Krishnasamy sits down with Resmi Charalel, MD MPH FSIR, and Milan Patel for a case-based discussion of their firsthand experience with Embrace HES. Thank you to Dr. Charalel, Dr. Patel, and Dr. Krishnasamy for sharing your experience with the IR community. Listen on BackTable: https://lnkd.in/guYMA3Uq This episode was produced by BackTable and sponsored by Instylla. Views expressed are those of the participating physicians. Please refer to the Embrace HES Instructions for Use (IFU) for complete information regarding indications, contraindications, warnings, precautions, and directions for use. #LiquidEmbolics #LiquidEmbolization #BackTable #InterventionalRadiology #Embolization #EmbraceHES

Embrace the Case. - 43-year-old female - Liver metastasis from breast cancer, Segment V - Unresectable, multiple prior chemotherapy regimens Treated with Embrace® HES. - 28% diameter reduction at 30 days - 45% diameter reduction at 90 days - No revascularization - No local tumor progression Conclusion: Transarterial embolization with Embrace® HES in managing unresectable liver metastases from breast cancer. Sustained tumor control with no contrast uptake or local progression through 90 days, and partial response by mRECIST criteria. View the full case: https://lnkd.in/grYuttAt #EmbraceHES #Instylla #InterventionalRadiology #Embolization #IR #InterventionalOncology #LiverMetastasis

In the Instylla HES Hypervascular Tumor Study, there was no clinically significant non-target embolization associated with Embrace® HES in 148 treated vessels. Proven in a prospective, randomized, multicenter pivotal trial. #EmbraceHES #InterventionalRadiology #Embolization #IR #ClinicalData

Embrace the Case. - 60-year-old female - Right renal angiomyolipoma, 4.6 cm - Focal and encapsulated Treated with Embrace® HES. - 44% diameter reduction at 30 days - 45% diameter reduction at 90 days - No revascularization - No local tumor progression Conclusion: Embolization of a renal angiomyolipoma with Embrace® HES achieved technical success with sustained tumor control. No evidence of local progression or recanalization at 30 or 90 days. View the Full Case: https://lnkd.in/gNgniAed #EmbraceHES #Instylla #InterventionalRadiology #Embolization #IR #InterventionalOncology #RenalAngiomyolipoma